Update on Partnership with 4TEEN4 Pharmaceuticals
Abingdon Health plc has provided an update on its partnership with 4TEEN4 Pharmaceuticals, confirming its role as the legal manufacturer and CDMO for the DPP3 InvoSelect companion diagnostic test, designed to identify patients who will benefit from 4TEEN4's invobenitug therapy. This collaboration leverages Abingdon Health's expertise in lateral flow development, regulatory strategy, and scaled manufacturing, with a focus on synchronised co-development to align the diagnostic and therapeutic timelines. The project is progressing well, with both companies highlighting the strong collaboration and technical capabilities involved in advancing this potentially life-saving therapy.
Select text to share a quote on X · sign in to keep highlights & notes in your ABDX notes
York, UK and Madison, WI, USA, 6 May 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, provides an update on its partnership with 4TEEN4 Pharmaceuticals GmbH ("4TEEN4"), a German biopharmaceutical company developing invobenitug (procizumab, AK1967), a first-in-class antibody therapy for life-threatening cardiogenic and septic shock.
This partnership was first announced via RNS on 12 June 2025, without giving details of the customer or project at that time for confidentiality reasons.
As legal manufacturer and CDMO partner, Abingdon Health is developing DPP3 InvoSelect, a lateral flow-based companion diagnostic (CDx) designed to identify the patients most likely to benefit from this targeted therapy.
The project brings together Abingdon Health's core capabilities:
- Lateral Flow Development: designing a scalable, easy-to-use assay with a customised reader for clear, unambiguous quantification of cDPP3 at the point of care.
- Regulatory Expertise: proactively engaging with regulatory agencies for technical advice and ensuring CDx strategy is tightly aligned with the drug development pathway.
- Manufacturing at Scale: building a test engineered for global distribution and consistent quality from day one.
- Synchronised Co-development: matching every CDx milestone to the drug's clinical timeline, because in a project like this, the two cannot be decoupled.
The challenge of synchronising diagnostic and therapeutic development is incredibly complex and demands experienced technical capability, deep regulatory understanding, genuine partnership, and rigorous project management.
The full case study is available at: Case Study: 4TEEN4 Companion Diagnostic Partnership - Abingdon Health plc
The Head of CDx at 4TEEN4 Pharmaceuticals commented: "The technical expertise and regulatory support provided by Abingdon Health have been invaluable in advancing our companion diagnostic project. Their commitment and collaborative approach have brought us significantly closer to delivering a life-saving therapy for patients in critical shock."
Chris Yates, Chief Commercial Officer at Abingdon Health plc, commented: "Companion diagnostics that are tightly co-developed alongside a therapeutic aren't just a technical challenge; they represent a genuine opportunity to change patient outcomes. We're proud to be 4TEEN4's CDMO partner on this programme, and the progress we've made together in aligning our CDx milestones with their clinical pathway reflects the depth of collaboration both teams are committed to. We look forward to continuing to advance this project toward the patients who need it most."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.